,a LANGE medical book
Katzung’s Basic
& Clinical
Pharmacology
Sixteenth Edition
Edited by
Todd W. Vanderah, PhD
Regents Professor and Chair
Department of Pharmacology
University of Arizona College of Medicine, Tucson
New York Chicago San Francisco Athens London Madrid Mexico City
Milan New Delhi Singapore Sydney Toronto
,Copyright © 2024 by McGraw Hill LLC. All rights reserved. Except as permitted under the Copyright Act of 1976, no part of this publication may be
reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of publisher.
ISBN: 978-1-26-046331-6
MHID: 1-26-046331-1
The material in this eBook also appears in the print version of this title: ISBN: 978-1-26-046330-9, MHID: 1-26-046330-3.
eBook conversion by codeMantra
Version 1.0
All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use
names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designa-
tions appear in this book, they have been printed with initial caps.
McGraw Hill eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To
contact a representative, please visit the Contact Us page at www.mhprofessional.com.
Notice
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are
required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is
complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes
in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work war-
rants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or
for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with
other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan
to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in
the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
TERMS OF USE
This is a copyrighted work and McGraw Hill (“McGraw Hill”) and its licensors reserve all rights in and to the work. Use of this work is subject to these
terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disas-
semble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work
or any part of it without McGraw Hill’s prior consent. You may use the work for your own noncommercial and personal use; any other use of the work
is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE
ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY IN-
FORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY
WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FIT-
NESS FOR A PARTICULAR PURPOSE.
McGraw Hill and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation
will be uninterrupted or error free. Neither McGraw Hill nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission,
regardless of cause, in the work or for any damages resulting therefrom. McGraw Hill has no responsibility for the content of any information accessed
through the work. Under no circumstances shall McGraw Hill and/or its licensors be liable for any indirect, incidental, special, punitive, consequential
or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This
limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.
, Contents
Preface ix
Authors xi
S E C T I O N I 10. Adrenoceptor Antagonist Drugs
Italo Biaggioni, MD 161
BASIC PRINCIPLES 1 S E C T I O N III
Introduction: The Nature of Drugs &
1.
CARDIOVASCULAR-RENAL
Drug Development & Regulation
Todd W. Vanderah, PhD, & DRUGS 177
Bertram G. Katzung, MD, PhD 1
11. Antihypertensive Agents
Drug Receptors & Pharmacodynamics
2. Neal L. Benowitz, MD 177
Mark von Zastrow, MD, PhD 21
Vasodilators & the Treatment of Angina
12.
Pharmacokinetics & Pharmacodynamics:
3. Pectoris & Coronary Syndromes
Rational Dosing & the Time Course Bertram G. Katzung, MD, PhD 200
of Drug Action
Nicholas H. G. Holford, MB, ChB, FRACP 42 13. Drugs Used in Heart Failure
Bertram G. Katzung, MD, PhD 219
Drug Biotransformation
4.
Maria Almira Correia, PhD 57 14. Agents Used in Cardiac Arrhythmias
Robert D. Harvey, PhD, &
Pharmacogenomics
5. Augustus O. Grant, MD, PhD 235
Jennifer E. Hibma, PharmD,
& Kathleen M. Giacomini, PhD 77 15. Diuretic Agents
Ramin Sam, MD, & David Pearce, MD 261
S E C T I O N II S E C T I O N IV
AUTONOMIC DRUGS 93
DRUGS WITH IMPORTANT ACTIONS
Introduction to Autonomic Pharmacology
6. ON SMOOTH MUSCLE 287
Todd W. Vanderah, PhD, &
Bertram G. Katzung, MD, PhD 93 16. H
istamine, Serotonin, Anti-Obesity
Drugs, & the Ergot Alkaloids
Cholinoceptor-Activating &
7. Bertram G. Katzung, MD, PhD 287
Cholinesterase-Inhibiting Drugs
Todd W. Vanderah, PhD 111 17. Vasoactive Peptides
Ian A. Reid, PhD 311
Cholinoceptor-Blocking Drugs
8.
Todd W. Vanderah, PhD 129 18. T
he Eicosanoids: Prostaglandins,
Thromboxanes, Leukotrienes, &
Adrenoceptor Agonists &
9. Related Compounds
Sympathomimetic Drugs John Hwa, MD, PhD, &
Italo Biaggioni, MD, & Kathleen Martin, PhD 338
Vsevolod V. Gurevich, PhD 142
v
Katzung’s Basic
& Clinical
Pharmacology
Sixteenth Edition
Edited by
Todd W. Vanderah, PhD
Regents Professor and Chair
Department of Pharmacology
University of Arizona College of Medicine, Tucson
New York Chicago San Francisco Athens London Madrid Mexico City
Milan New Delhi Singapore Sydney Toronto
,Copyright © 2024 by McGraw Hill LLC. All rights reserved. Except as permitted under the Copyright Act of 1976, no part of this publication may be
reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of publisher.
ISBN: 978-1-26-046331-6
MHID: 1-26-046331-1
The material in this eBook also appears in the print version of this title: ISBN: 978-1-26-046330-9, MHID: 1-26-046330-3.
eBook conversion by codeMantra
Version 1.0
All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use
names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designa-
tions appear in this book, they have been printed with initial caps.
McGraw Hill eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To
contact a representative, please visit the Contact Us page at www.mhprofessional.com.
Notice
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are
required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is
complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes
in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work war-
rants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or
for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with
other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan
to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in
the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
TERMS OF USE
This is a copyrighted work and McGraw Hill (“McGraw Hill”) and its licensors reserve all rights in and to the work. Use of this work is subject to these
terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disas-
semble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work
or any part of it without McGraw Hill’s prior consent. You may use the work for your own noncommercial and personal use; any other use of the work
is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE
ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY IN-
FORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY
WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FIT-
NESS FOR A PARTICULAR PURPOSE.
McGraw Hill and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation
will be uninterrupted or error free. Neither McGraw Hill nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission,
regardless of cause, in the work or for any damages resulting therefrom. McGraw Hill has no responsibility for the content of any information accessed
through the work. Under no circumstances shall McGraw Hill and/or its licensors be liable for any indirect, incidental, special, punitive, consequential
or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This
limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.
, Contents
Preface ix
Authors xi
S E C T I O N I 10. Adrenoceptor Antagonist Drugs
Italo Biaggioni, MD 161
BASIC PRINCIPLES 1 S E C T I O N III
Introduction: The Nature of Drugs &
1.
CARDIOVASCULAR-RENAL
Drug Development & Regulation
Todd W. Vanderah, PhD, & DRUGS 177
Bertram G. Katzung, MD, PhD 1
11. Antihypertensive Agents
Drug Receptors & Pharmacodynamics
2. Neal L. Benowitz, MD 177
Mark von Zastrow, MD, PhD 21
Vasodilators & the Treatment of Angina
12.
Pharmacokinetics & Pharmacodynamics:
3. Pectoris & Coronary Syndromes
Rational Dosing & the Time Course Bertram G. Katzung, MD, PhD 200
of Drug Action
Nicholas H. G. Holford, MB, ChB, FRACP 42 13. Drugs Used in Heart Failure
Bertram G. Katzung, MD, PhD 219
Drug Biotransformation
4.
Maria Almira Correia, PhD 57 14. Agents Used in Cardiac Arrhythmias
Robert D. Harvey, PhD, &
Pharmacogenomics
5. Augustus O. Grant, MD, PhD 235
Jennifer E. Hibma, PharmD,
& Kathleen M. Giacomini, PhD 77 15. Diuretic Agents
Ramin Sam, MD, & David Pearce, MD 261
S E C T I O N II S E C T I O N IV
AUTONOMIC DRUGS 93
DRUGS WITH IMPORTANT ACTIONS
Introduction to Autonomic Pharmacology
6. ON SMOOTH MUSCLE 287
Todd W. Vanderah, PhD, &
Bertram G. Katzung, MD, PhD 93 16. H
istamine, Serotonin, Anti-Obesity
Drugs, & the Ergot Alkaloids
Cholinoceptor-Activating &
7. Bertram G. Katzung, MD, PhD 287
Cholinesterase-Inhibiting Drugs
Todd W. Vanderah, PhD 111 17. Vasoactive Peptides
Ian A. Reid, PhD 311
Cholinoceptor-Blocking Drugs
8.
Todd W. Vanderah, PhD 129 18. T
he Eicosanoids: Prostaglandins,
Thromboxanes, Leukotrienes, &
Adrenoceptor Agonists &
9. Related Compounds
Sympathomimetic Drugs John Hwa, MD, PhD, &
Italo Biaggioni, MD, & Kathleen Martin, PhD 338
Vsevolod V. Gurevich, PhD 142
v
